Figure 5 | Scientific Reports

Figure 5

From: Biogenic amine tryptamine in human vaginal probiotic isolates mediates matrix inhibition and thwarts uropathogenic E. coli biofilm

Figure 5

Inhibition of Matrix and biofilm formation by Tryptamine. (A) Crystal Violet Assay, 0,5% of DMSO which was used as a solvent to dissolve tryptamine acted as vehicle negative control (B) Matrix inhibition, where (a) Control E. coli UTI89 shows Red, Dry and Rough (RDAR) colony morphology indicate matrix production (b) and (c) C2 Tryptamine and Commercial tryptamine present in CFS Smooth and White (SAW) colony morphology indicate absence of matrix (C) The influence of tryptamine on biofilm development stages; (1) Adhesion (2) Mature (3) Dispersal n = 3,Statistical significance were analysed using one-way ANOVA***p < 0.001 (D) MTT assay showing Percentage Viability of preformed biofilm of E. coli UTI89 following treatment with Lactobacillus extracted tryptamine (Lacto. Tryptamine) and commercial tryptamine compared to untreated and positive control (EDTA-0.1%) conditions. Error bars represent the standard deviation from the mean (n = 3).

Back to article page